The Supreme Court of India has raised concerns about the financial burden of high medicine prices, questioning whether the existing regulatory framework adequately protects patients, particularly those undergoing expensive cancer treatment.
A bench comprising Justices Vikram Nath and Sandeep Mehta was hearing petitions concerning medicine-price regulation, generic prescriptions and trade margins on medicines and medical devices.
Editorial Insight
Key Highlights
Important points readers should notice.
Issue/Event: The Supreme Court questioned steep differences between medicine procurement prices and charges billed to patients.
Location: Supreme Court of India, New Delhi.
Authority/Organisation: Supreme Court of India and the Union government’s pharmaceutical-pricing authorities.
Action Taken: The court heard petitions seeking stronger regulation of medicine prices and reserved its order.
Impact: The proceedings could influence future policy on medicine affordability, trade margins and patient protection.
During the proceedings, the bench referred to a case in which a medical distributor reportedly offered to supply a cancer injection for ₹11,000, but a private hospital charged ₹1.30 lakh for administering it to his wife, who was undergoing cancer treatment. The example prompted questions about the justification for such a large difference.
The court also examined the gap between the maximum retail price (MRP) and the price to retailer (PTR), asking the government to explain how the current system operates and whether the rules provide sufficient protection against excessive mark-ups.
Government Defends Its Approach
Editorial Analysis
Why This Matters
High medicine costs can place considerable pressure on families, especially when treatment involves cancer medicines and other expensive therapies. Patients may have limited ability to compare prices or negotiate charges during urgent treatment. The case puts the spotlight on how medicine prices are determined, how hospitals account for medicines supplied to patients and whether existing safeguards are sufficient. However, procurement prices and hospital charges may involve different services and costs. The example cited in court is an allegation presented during proceedings, not a finding that every hospital applies similar mark-ups.
Representing the Centre, Additional Solicitor General Aishwarya Bhati argued that the government’s approach seeks to balance affordability with competition, investment and the wider pharmaceutical ecosystem. The government also maintained that India has relatively low medicine prices compared with many other countries.
The bench questioned why price regulation does not cover a wider range of medicines and referred to concerns raised in earlier reports about drug pricing.
The hearing also examined the government’s decision to cap trade margins at 30% of MRP for 137 anti-cancer medicines. The court questioned why similar protections could not be considered more broadly.
What Happens Next?
The court reserved its order after hearing the parties. The proceedings therefore do not themselves establish new nationwide price limits or a final ruling against hospitals.
The case could have important implications for future medicine-pricing policy, including the regulation of non-scheduled medicines, generic prescriptions and trade margins. The outcome will depend on the court’s eventual order and any subsequent government action.
